Welcome to our dedicated page for So-Young International news (Ticker: SY), a resource for investors and traders seeking the latest updates and insights on So-Young International stock.
So-Young International Inc. reports on its China aesthetic treatment platform, which connects consumers with online services and offline treatments through digital access points and branded aesthetic centers. Company updates cover curated treatment information, online reservations, aesthetic treatment services, and the development, production and distribution of optoelectronic medical equipment and injectable products.
Recurring news themes include quarterly and annual results, branded center expansion, platform transaction activity, treatment visits, active users, member activity, and operating performance across medical aesthetics services. So-Young also reports foreign-issuer and ADS-related matters, including annual Form 20-F filing announcements and completed Nasdaq listing compliance updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
So-Young International Inc. (NASDAQ: SY) announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the Securities and Exchange Commission on April 25, 2023. The report is accessible on the company’s investor relations website. Shareholders and ADS holders can obtain a hard copy of the annual report, which contains audited financial statements, by request. As a leader in China's medical aesthetics social community, So-Young provides reliable information and vetted services to users, aiming to expand within the medical aesthetic industry and the growing consumption healthcare market.
So-Young International Inc. (Nasdaq: SY) reported unaudited financial results for Q4 and FY 2022, revealing total revenues of RMB325.1 million (US$47.1 million) for Q4, down 27.7% year-over-year. The company achieved a net income of RMB31.3 million (US$4.5 million), reversing a loss of RMB27.7 million in Q4 2021. However, FY 2022 revenues declined 25.7% to RMB1,257.9 million (US$182.4 million), with a net loss of RMB65.6 million (US$9.5 million) compared to a loss of RMB8.4 million in FY 2021. The company holds a solid cash balance of RMB1.6 billion, providing potential growth opportunities in 2023. Looking ahead, So-Young expects Q1 2023 revenues between RMB290 million (US$42.0 million) and RMB310 million (US$44.9 million).
So-Young International Inc. (NASDAQ: SY) has announced it will report its financial results for the fourth quarter and full year ended December 31, 2022, on March 21, 2023. The earnings conference call will take place at 7:30 AM U.S. Eastern Time. This report will provide insights into the company's performance in the medical aesthetics industry, the largest social community in China. Investors can access a live and archived webcast of the call via the company's investor relations website.
So-Young International Inc. (Nasdaq: SY) has announced its compliance with Nasdaq's minimum bid price requirement of US$1.00 per share, effective January 4, 2023. Previously notified of non-compliance on July 15, 2022, the Company regained compliance after the closing bid price remained above US$1.00 for 11 consecutive business days from December 16, 2022, to January 3, 2023. Nasdaq has deemed this matter closed, which is a positive development for the Company.
So-Young International Inc. (Nasdaq: SY) has increased its Share Repurchase Program from US$15 million to US$25 million. This decision reflects the Company's confidence in its long-term prospects within the expanding medical aesthetics market. The program is effective for 12 months starting from November 18, 2022, allowing repurchases in various market conditions. So-Young aims to fund these repurchases from its cash balance, highlighting its commitment to enhancing shareholder value.